The United States influenza vaccines market size to cross US$ 5.5 Billion by 2028.
This new market report presents an inclusive study of the entire United States influenza vaccines market. The report offers the most up–to–date industry data on the actual market situation and future outlook for the United States influenza vaccines market. The report also provides up–to–date market size data for the period 2015 – 2020 and an illustrative forecast to 2028 covering key market aspects like market value and volume for influenza vaccines.
Some of the Major Factors Contributing to the Growth of the Market:
• The Surge in the COVID–19 Pandemic
• Increased Disease Awareness
• Introduction of the Quadrivalent Influenza Vaccines
• Increasing Research and Development
• Expanded Recommendations by Governmental and Advisory Bodies to be Vaccinated against Influenza Vaccines
Key Highlights:
• The United States Rises to Become Largest Influenza Vaccines Market
• The Demand for the Flu Vaccine is Expected to Increase in the Forecast Period Because of the COVID–19 Pandemic Surge
• EpiVax to Design Antigens for Next–Generation Flu Vaccine
• Versatope Therapeutics, Inc Awarded a Contract worth up to US$17.9 Million from the National Institute of Allergy and Infectious Diseases (NIAID)
This Comprehensive U.S Influenza Vaccines Report Provides:
• The Market Size of the United States Influenza Vaccines Market with Seven Years Forecast
• Evaluates the United States Overall Persons Being Vaccinated with Influenza Vaccines with Seven Years Forecast
• Scrutinizes the United States Children Being Vaccinated with Influenza Vaccines with Seven Years Forecast
• Studies the United States Adults Being Vaccinated with Influenza Vaccines with Seven Years Forecast
• Delivers Comprehensive Insights on the Latest Pricing Trends and Analysis
• Covers a Broad Analysis of the US Influenza Vaccines Production, Supply, and Allocation (By Companies)
• Delivers a Complete Outline of the US Influenza Vaccines Distribution and Demand
• Studies the Latest Effectiveness of the Influenza Vaccines in the United States
• Thoroughly Assessment of the Rapid Diagnostic Testing for the Management of Influenza
• Meticulously Assesses of the Distribution Channel and Technique of the Influenza Vaccination in the United States
• Detailed Insights into the Regulatory Framework of the United States Influenza Vaccines Market
• Features Reimbursement Patterns of the United States Influenza Vaccines Market
• Tracks Competitive Developments, Approaches, Recent Industry Developments, Mergers & Acquisitions. Collaboration, Distribution, Exclusive, and Licensing Agreement
• An Insightful Investigation has been done on Promising Influenza Vaccines in the Clinical Development
• Analyses the Most Recent Clinical Trials of the Influenza Vaccines between 2019 and 2020
• Delivers an In–Depth Analysis of Evolving Market Trends, Drivers, and Restraints of the United States Influenza Vaccines Market
• A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolio, Promising Vaccines in the Clinical Development, Influenza Vaccines Market Value, and Recent Development
• An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development
The Key and Emerging Market Players for the U.S Influenza Vaccines Market are Listed Below :
• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Seqirus (CSL Limited)
• AstraZeneca
• EpiVax, Inc
• Novavax
• Medicago
• Moderna Inc
• Pneumagen
• Daiichi–Sankyo
• Altimmune
• FluGen
• Imutex
• Versatope Therapeutics, Inc
• BiondVax Pharmaceuticals Ltd.
Key Questions Answered in this Report:
• What is the current scenario of the U.S. influenza vaccines market?
• What is the total market size and forecast (until 2028) for the U.S. influenza vaccines market?
• How many persons being vaccinated with influenza vaccines in the US during 2015 – 2028?
• How effective is influenza(flu) shot for 2020?
• What percentage of the United States do people get the flu vaccine?
• What are the key marketed influenza vaccines available in the United States?
• What are the major drivers of the United States influenza vaccines market?
• What are the major inhibitors of the United States influenza vaccines market?
• What is the reimbursement pattern in the United States influenza vaccines market?
• What is the regulatory framework in the United States influenza vaccines market?
• What are the major deals and agreement happenings in the United States influenza vaccines market?
• What are the upcoming influenza vaccines that will have a significant impact on the market in the future?
• Who are the top market players? What are their happenings, vaccine revenue, current developments, and scenarios?
• Who are the emerging players? What are their happenings, clinical development, platform technology, phase, and current developments?
• How is the market predicted to develop in the future?
'
1. Executive Summary
2. United States Influenza Vaccines Market Size and Forecasts (2015 – 2028)
3. United States Number of Persons Vaccinated with Influenza Vaccines (2015 – 2028)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines
4. Key Drivers and Inhibitors of the United States Influenza Vaccines Market
4.1 Market Drivers
4.2 Market Restraints
5. United States Influenza Vaccines Pricing Trends & Analysis
6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
7. United States Influenza Vaccines Distribution & Demand (2010 – 2021)
8. Effectiveness of Influenza Vaccines in the United States (2004 – 2021)
9. Rapid Diagnostic Testing for the Management of Influenza
10. Distribution Channel and Technique of Influenza Vaccination in the United States
11. Reimbursement Environment of the United States Influenza Vaccines Market
12. Regulatory Framework of the United States Influenza Vaccines Market
13. Major Deals and Agreement Happenings in the Influenza Vaccines Market
13.1 Merger & Acquisitions
13.2 Collaboration Deal
13.3 Licensing Agreement
13.4 Exclusive Agreement
13.5 Distribution Agreement
14. Promising Influenza Vaccines in the Clinical Development
15. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
15.1 Year 2020
15.2 Year 2019
16. Key Players Analysis
16.1 Sanofi Pasteur
16.1.1 Business Overview
16.1.2 Influenza Vaccines Portfolio
16.1.3 Influenza Vaccines Sales Value Analysis
16.1.4 Promising Influenza Vaccines in the Clinical Development
16.1.5 Recent Development
16.2 GlaxoSmithKline (GSK)
16.2.1 Business Overview
16.2.2 Influenza Vaccines Portfolio
16.2.3 Influenza Vaccines Sales Value Analysis
16.2.4 Recent Development
16.3 Seqirus
16.3.1 Business Overview
16.3.2 Influenza Vaccines Portfolio
16.3.3 Influenza Vaccines Sales Value Analysis
16.3.4 Promising Influenza Vaccines in the Clinical Development
16.3.5 Recent Development
16.4 AstraZeneca
16.4.1 Business Overview
16.4.2 Influenza Vaccines Portfolio
16.4.3 Influenza Vaccines Sales Value Analysis
16.4.4 Recent Development
17. Emerging Players
17.1 Novavax
17.1.1 Business Overview
17.1.2 Promising Influenza Vaccines in the Clinical Development
17.1.3 Recent Development
17.2 BiondVax Pharmaceuticals Ltd.
17.2.1 Business Overview
17.2.2 Promising Influenza Vaccines in the Clinical Development
17.2.3 Recent Development
17.3 Medicago
17.3.1 Business Overview
17.3.2 Promising Influenza Vaccines in the Clinical Development
17.3.3 Recent Development
17.4 Moderna Inc
17.4.1 Business Overview
17.4.2 Promising Influenza Vaccines in the Clinical Development
17.4.3 Recent Development
17.5 Pneumagen
17.5.1 Business Overview
17.5.2 Promising Influenza Vaccines in the Clinical Development
17.5.3 Recent Development
17.6 Altimmune
17.6.1 Business Overview
17.6.2 Promising Influenza Vaccines in the Clinical Development
17.6.3 Recent Development
17.7 Daiichi Sankyo
17.7.1 Business Overview
17.7.2 Promising Influenza Vaccines in the Clinical Development
17.7.3 Recent Development
17.8 FluGen
17.8.1 Business Overview
17.8.2 Promising Influenza Vaccines in the Clinical Development
17.8.3 Recent Development
17.9 Imutex
17.9.1 Business Overview
17.9.2 Promising Vaccines in the Clinical Development
17.9.3 Recent Development
17.10 EpiVax
17.10.1 Business Overview
17.10.2 Promising Influenza Vaccines in the Clinical Development
17.10.3 Recent Development
17.11 Versatope Therapeutics, Inc
17.11.1 Business Overview
17.11.2 Promising Influenza Vaccines in the Clinical Development
17.11.3 Recent Development
List of Tables:
Table 5–1: United States Pediatric Influenza Vaccines Price, 2021 – 2022
Table 5–2: United States Adult Influenza Vaccine Price, 2021 – 2022
Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation
Table 7–1: Total Percentage of Influenza Vaccines Released by Week, 2020 – 2021
Table 7–2: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020
Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2018 – 2019
Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 7–5: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 7–6: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 7–7: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2021
Table 9–1: Influenza Virus Testing Methods
Table 10–1: Distribution of Influenza Vaccination
Table 12–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 13–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 13–2: Collaboration Deal in the Influenza Vaccines Market
Table 13–3: Licensing Agreement in the Influenza Vaccines Market
Table 13–4: Exclusive Agreement in the Influenza Vaccines Market
Table 13–5: Distribution Agreement in the Influenza Vaccines Market
Table 14–1: BiondVax Pharmaceuticals Ltd. – Clinical Trials
Table 16–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 16–2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 17–1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 17–2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 17–3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 17–4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 17–5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 17–6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 17–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 17–8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 17–9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 12–10: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 12–11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
List of Figures:
Figure 2–1: United States Influenza Vaccines Market (Million US$),2015 – 2020
Figure 2–2: United States Influenza Vaccines Market Forecast (Million US$),2021 – 2028
Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2028
Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2015 – 2020
Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2021 – 2028
Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2015 – 2020
Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2021 – 2028
Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2021
Figure 10–1: United States Place of Influenza Vaccination for Children and Adults (Percent),2019 – 2020
Figure 16–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 16–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2028
Figure 16–3: GSK Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 16–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2028
Figure 16–5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 16–6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2028
Figure 16–7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 16–8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2028
